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The extracellular form of the abundant heat-shock protein, gp96, is involved in human
autoimmune pathologies. In patients with type 1 diabetes, circulating gp96 is found to be
elevated, and is bound to the acute-phase protein, α1-antitrypsin (AAT).The two molecules
also engage intracellularly during the physiological folding of AAT. AAT therapy promotes
pancreatic islet survival in both transplantation and autoimmune diabetes models, and
several clinical trials are currently examining AAT therapy for individuals with type 1 dia-
betes. However, its mechanism of action is yet unknown. Here, we examine whether the
protective activity of AAT is related to binding of extracellular gp96. Primary mouse islets,
macrophages, and dendritic cells were added recombinant gp96 in the presence of clinical-
grade human AAT (hAAT, Glassia™, Kamada Ltd., Israel). Islet function was evaluated by
insulin release. The effect of hAAT on IL-1β/IFNγ-induced gp96 cell-surface levels was also
evaluated. In vivo, skin transplantation was performed for examination of robust immune
responses, and systemic inflammation was induced by cecal puncture. Endogenous gp96
was inhibited by gp96-inhibitory peptide (gp96i, Compugen Ltd., Israel) in an allogeneic
islet transplantation model. Our findings indicate that hAAT binds to gp96 and diminishes
gp96-induced inflammatory responses; e.g., hAAT-treated gp96-stimulated islets released
less pro-inflammatory cytokines (IL-1β by 6.16-fold and TNFα by 2.69-fold) and regained
gp96-disrupted insulin release. hAAT reduced cell activation during both skin transplan-
tation and systemic inflammation, as well as lowered inducible surface levels of gp96
on immune cells. Finally, inhibition of gp96 significantly improved immediate islet graft
function. These results suggest that hAAT is a regulator of gp96-mediated inflammatory
responses, an increasingly appreciated endogenous damage response with relevance to
human pathologies that are exacerbated by tissue injury.
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INTRODUCTION
Pancreatic islet transplantation can afford tight physiological
blood glucose control for individuals with type 1 diabetes, pro-
vided that the grafted islets survive multiple inflammatory, innate,
and immune-mediated injurious processes. During the initial
stages of islet engraftment, prior to lymphocytic antigen recog-
nition, macrophages and dendritic cells amplify the inflammatory
state of graft microenvironment, causing the loss of up to 60%
of the transplanted islet mass (1). The trigger for cell activa-
tion falls under the category of sterile inflammation, instigated
by injured and necrotic isolation-processed islets. Indeed, it has
been shown that inflammation from damaged foci readily spreads
to neighboring islets independent of adaptive immune responses;
these neighboring islets in turn become new foci of inflammation
(2). Current treatment protocols that accompany islet transplanta-
tion predominantly target adaptive immune responses and exhibit
limited outcomes, as well as pose a direct threat to islet β-cell via-
bility (3–5); inflammation, on the other hand, is left primarily
unopposed, as corticosteroid therapy is contraindicated (6).
Upstream events that govern sterile inflammation involve
endogenous alarmin molecules, or damage associated molecular
pattern (DAMP) molecules (7, 8). For example, heat-shock pro-
tein gp96 is an abundant chaperone in the endoplasmic reticulum
in a wide variety of mammalian cells, and its intracellular levels
rise appropriately during stress conditions such as inflammation,
hypoxia, or glucose starvation (9). However, under certain condi-
tions, gp96 is found outside the cells and on the membranes of
some immune cells. Recently, evidence for aberrant extracellular
functions of gp96 have emerged, suggesting that once exiting the
cells, gp96 behaves as a DAMP molecule.
Extracellular gp96 binds to TLR2/4 and to CD91, which in
turn facilitate an increase in the release of pro-inflammatory
cytokines (10, 11). Extracellular gp96 is obtained by both pas-
sive release from leaky cell membranes of affected necrotic cells,
and by production of an inducible membrane-bound form under
particular conditions (12, 13). In mice genetically engineered to
possess antigen-presenting cells (APCs) that express gp96 on their
membranes, systemic lupus erythematosus (SLE) symptoms are
observed (12). Accordingly,APCs collected from these mice release
high levels of pro-inflammatory mediators. In humans, Pope et al.
described high levels of gp96 in synovial fluids from patients with
rheumatoid arthritis (RA) compared to samples obtained from
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patients with osteoarthritis; the collected synovial gp96 was then
shown to evoke an inflammatory response in human macrophages
in the form of elevated TLR2, IL-6, and TNFα. Consistent with
these findings, patients with type 1 diabetes exhibit high levels of
circulating gp96, supporting the increasing notion that there exists
a role for DAMPs in autoimmune conditions (14).
Extracellular gp96 has been detected in the circulation of
patients with type 1 diabetes bound to the acute-phase protein α1-
antitrypsin (AAT) (14). AAT is an anti-inflammatory protein that
circulates at>1 mg/ml, second only to albumin and immunoglob-
ulins in its levels. AAT is readily available for the treatment of the
rare genetic deficiency in the protein, for which the material is
provided in the form of plasma-derived affinity-purified human
AAT (hAAT).
In recent years, several activities were observed that render
hAAT an attractive candidate for a series of inflammatory condi-
tions, as recently reviewed (15). In particular, a benefit appears to
emerge in conditions that combine tissue damage and inflamma-
tion, such as in ischemic myocardium (16) and graft-versus-host
disease (17). Evidence is most abundant, however, in the ability of
hAAT to modify the adaptive immune response in favor of pancre-
atic islet survival; hAAT exerts protective activities in the context
of autoimmune diabetes and islet alloimmune responses (18–22),
and three independent trials are currently ongoing for hAAT ther-
apy in newly diagnosed type 1 diabetes patients (NIH clinical trial
registry NCT01304537, NCT01319331, and NCT01183468). Our
group has demonstrated that hAAT also facilitates immune tol-
erance in several non-diabetes-related models (23, 24) and that
hAAT affords strain-specific immune tolerance by targeting non-
T cells. Indeed, hAAT appears to target predominantly APCs, as
macrophages and dendritic cells.
In the present study, we examine whether the protective activ-
ities of hAAT may be derived from direct inhibition of gp96-
mediated inflammatory responses, in the context of pancreatic
islet transplantation.
MATERIALS AND METHODS
ANIMALS
Six to eight-week-old male C57BL/6 mice (Harlan Laboratories
Ltd., Israel) were used as graft recipients and participated in the
cecal puncture (CP) model. Pancreatic islets were isolated from 8-
to 10-week-old CBA/2J mice (Jackson laboratory, Bar Harbor, ME,
USA). Skin grafts were obtained from 8- to 10-week-old BALB/c
mice (Harlan Laboratories Ltd.). Experiments were approved by
the Ben-Gurion University of the Negev Animal Care and Use
Committee.
PANCREATIC ISLET ISOLATION
Pancreatic islets were isolated as described (20). Briefly, donor
mice were anesthetized, pancreata were inflated with collage-
nase (1 mg/ml, type XI, Sigma-Aldrich), excised, and incubated
for 40 min at 37°C. Digested pancreata were vortexed and fil-
tered through a 500-µm sieve, and the pellet was washed in
HBSS containing 0.5% BSA (Sigma-Aldrich). The pellet was resus-
pended in RPMI 1640 medium supplemented with 10% FCS,
50 units/ml penicillin, and 50µg/ml streptomycin (all from Cell-
gro, Mediatech, Herndon, VA, USA). Islets were collected on a
100-µm cell strainer (BD, Falcon) and then hand-picked under a
stereomicroscope.
ISLET ALLOGRAFT TRANSPLANTATION
Recipient mice were rendered hyperglycemic by single streptozo-
tocin injection (STZ, 225 mg/kg i.p., Sigma-Aldrich), and islets
were grafted under the renal capsule, as described (20). Briefly,
hyperglycemic recipient mice were anesthetized, and 500 islets
were released into the renal subcapsular space, which was immedi-
ately sealed with 1-mm3 sterile absorbable gelatin sponge (Surgi-
foam, Ethicon, Somerville, NJ, USA). Blood glucose levels were
determined daily from tail blood using a standard glucometer
(Roche).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Immunohistochemistry staining was performed as described (25).
Briefly, explanted kidneys carrying implants were fixed in 10% for-
malin (Sigma-Aldrich) for 24 h and transferred into 70% ethanol.
The specimens were cut through the center of the implant,
embedded in paraffin, and sectioned. For histological exami-
nation, Hematoxylin and Eosin (H&E) was performed. Insulin
immunostaining was performed using guinea-pig-anti-swine-
insulin, detected by Cy3-donkey-anti-guinea-pig (both 1:200,
DakoCytomation, Glostrup, Denmark); nuclei were depicted by
4′,6-diamidino-2-phenylindole (DAPI) staining (1µg/ml, Sigma-
Aldrich). Immunofluorescence was detected using Olympus BX60
(Olympus UK Ltd., London, UK).
Gp96-RELATED REAGENTS
Recombinant human gp96 was from Proteintech, IL, USA. Endo-
toxin content was below 0.125 EU/ml at the concentrations used
(LAL assay, Pyrotell®, East Falmouth, MA, USA). In addition,
the recombinant protein was pretreated with PolymixenB (Sigma-
Aldrich). Inhibitor of gp96 (gp96i; 37 amino-acid-long synthetic
peptide II) was obtained from Compugen Ltd., Israel, described
elsewhere (26).
MACROPHAGE ACTIVATION STUDY
Thioglycolate (3% v/v 72 h)-elicited peritoneal macrophages were
collected by lavage and then further enriched using CD11b MACS
bead-enrichment kit. Cells were then seeded (4× 105 per well
in 48-well plate or 2× 106 per well in 6-well plate) in RPMI
1640 medium supplemented with 5% FCS, 50 units/ml penicillin,
and 50µg/ml streptomycin, in the presence or absence of various
concentrations of recombinant gp96.
Cytokine analysis
Supernatants were collected 24 h later and analyzed by Q-Plex
mouse cytokine chemiluminescence-based 8-p ELISA (Quan-
sys Biosciences, Logan, UT, USA). Each cytokine was quanti-
fied by densitometry using Quansys Q-View software (Quansys
Biosciences).
FACS analysis
Macrophages (1× 106 per sample) were stained with a com-
bination of anti-CD11b-Pacific Blue, anti-F4/80-APC and anti-
MHCII-APC/Cy7, anti-CD40-PE/Cy7, or anti-TLR4-PE/Cy7, and
Frontiers in Immunology | Inflammation October 2013 | Volume 4 | Article 320 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ochayon et al. α1-antitrypsin protects from gp96-mediated injury
anti-TLR2-FITC (all antibodies obtained from Biolegend®).
Antibodies were diluted to recommended concentration according
to manufacturer’s instructions. Non-specific staining was excluded
using matching isotype control antibodies (Biolegend®). Non-
specific Fc staining was minimized by addition of Fc-blocking
antibodies. Samples were analyzed by FACScalibur and BD Canto
II; BD Biosciences. Data were analyzed by BD CellQuest Pro or
FlowJo (version 7.6.5; Tree Star, Ashland, OR, USA).
CECAL PUNCTURE MODEL
A modification was made to the cecal and ligation model (27)
with the aim of achieving a non-lethal tissue-damage-associated
inflammatory model. Briefly, animals were anesthetized, the
cecum was identified,and then punctured once with a 21-gage nee-
dle. A 1 mm-long section of feces was extruded, and the abdominal
incision was closed using 3-0 nylon suture. Unlike in the complete
ligation model, all mice survive the modified procedure. Recombi-
nant gp96 (80µg/kg) was introduced i.p. 24 h after CP, peritoneal
lavage was performed 72 h after CP and then peritoneal cells were
analyzed by FACS.
Gp96 ACTIVITY ASSAYS IN VITRO
Islet cultures
Thirty islets per well in quadruplicate were stimulated with 50 pM
recombinant gp96 in the absence or presence of 3.3µM gp96i.
Supernatants were collected 24 h later for analysis by Q-Plex mouse
cytokine chemiluminescence-based 8-p ELISA. Each cytokine was
quantified by densitometry using Quansys Q-View software. Nitric
oxide levels were evaluated by Griess reagent assay (Promega,
WI, USA). Insulin levels were determined using specific ELISA
(Mercodia, Sweden).
Macrophage-islet co-cultures
Thirty islets were cultured in quadruplicate in the presence or
absence of primary macrophages (4× 105), with or without
recombinant gp96 and treated in the presence or absence of gp96i
at indicated concentrations.
BONE MARROW DERIVED DENDRITIC CELLS
Bone marrow derived dendritic cells (BMDC) were generated
from mice as described (28). Briefly, bone marrow from the
femurs and tibiae of C57BL/6 mice were washed in HBSS
and cultured on 100 mm plates in batches of 2× 106 BM cells
per plate in R10F (RPMI 1640 medium containing 2 mM l-
glutamine, 50 units/ml penicillin, 50µg/ml streptomycin, and
10% heat-inactivated FBS) with the addition of fresh 50µM
β2-mercaptoethanol and 20 ng/ml recombinant mouse GMCSF
(Prospec, Israel).
hAAT ACTIVITY ASSAYS
Acellular gp96:hAAT binding assay
ELISA-plate wells were coated with gp96 (0.05–4µg/ml) for 16 h at
room temp. Blocking of non-specific interactions was achieved by
incubation with 3% BSA solution (Sigma-Aldrich) for 2 h. Inter-
action between gp96 and hAAT (Glassia™, Kamada Ltd., Israel,
1µg/ml) was allowed to occur for 2 h and hAAT detection was per-
formed by HRP-conjugated anti-hAAT antibody (ICL, Portland,
OR, USA).
hAAT binding to cell membrane
Peritoneal macrophages (2× 106 per well) were introduced to
hAAT (0.5 mg/ml) for 16 h. Cells were stained with a combination
of anti-F4/80-APC and anti-hAAT-FITC (Bethyl, Montgomery,
TX, USA) and analyzed by FACS.
SKIN TRANSPLANTATION MODEL
Allogeneic skin transplantation was performed between major
MHC disparate mouse strains in order to evoke a potent and read-
ily detectable immune response (skin donors: BALB/c, H-2d; skin
recipients: C57BL/6, H-2b). Briefly, uniform 1 mm3 skin grafts
were fixed into the inside wall of the peritoneal cavity of recipi-
ent mice, and the immune infiltrate was recovered by lavage and
analyzed.
IN VIVO gp96i TREATMENT PROTOCOL
Mice were either injected with a daily dose of gp96i (4 mg/kg/day)
dissolved in PBS (Biological industries, Israel) for 7 days, or were
introduced with a 14-day osmotic pump containing a total of
1.4 mg gp96i (Alzet®, Cupertino, CA, USA), which distributed a
continuous dose once implanted, equivalent to the injected 7-day
protocol of 100µg/day. The 7-day experiment was followed by
animal harvest and splenocyte analysis for which cells were cul-
tured on a 48-well plate (4× 105 cells per well), then supernatants
were collected after 24 h, and analyzed by Q-Plex mouse cytokines
chemiluminescence-based 14-p ELISA.
STATISTICS
Comparisons between groups were performed by two-tailed
Mann-Whitney U test or using Student’s t -test p< 0.05 was con-
sidered statistically significant. Statistical analysis was performed
with GraphPad Prism 5.0 software.
RESULTS
INFLAMMATORY RESPONSES INDUCED BY gp96 ARE REGULATED BY
hAAT IN VITRO
In order to determine whether exogenous gp96 induces an inflam-
matory response in murine macrophages, peritoneal macrophages
were stimulated with several concentrations of polymixen B-
pretreated recombinant gp96 (5–500 pM) followed by nitrile
release assay 24 h later. As shown in Figure 1A, exogenous gp96
exerted an inflammatory response in a dose dependent manner,
and a significant increase in nitrile release was observed at 50 pM
and higher.
We next examined whether hAAT might reduce the inflam-
matory responses mediated by gp96 in peritoneal macrophages.
Cell cultures were pretreated with or without hAAT (0.5 mg/ml,
Glassia™, Kamada Ltd., Israel) overnight, then introduced to gp96
(50 pM) for 48 h. The inflammatory response was evaluated by
cytokine accumulation and by surface expression of immune cell
activation markers. As shown in Figure 1B, gp96 increased the
release of inflammatory mediators (IL-1β 2.67± 0.5-fold, IL-17
7.6± 0.06-fold, and TNFα 15.94± 0.36-fold, compared to control
untreated cells). In contrast, cultures that were stimulated by gp96
in the presence of hAAT displayed a decrease in the release of pro-
inflammatory cytokines (IL-1β by 1.38± 0.18, IL-17 by 2.41± 0.1,
and TNFα 1.36± 0.01, compared to gp96-stimulated cells); addi-
tionally, a rise was detected in the anti-inflammatory cytokine,
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FIGURE 1 | Exogenous gp96 mediates inflammatory responses in
peritoneal macrophages. (A) Dose response curve. Peritoneal macrophages
(4×105 per well in quadruplicates) were incubated in the presence of gp96
(0–500 pM, indicated) for 24 h. Nitrile release to supernatants was evaluated
by Griess assay. Shown are representative results of four independent
experiments. (B) Release of inflammatory mediators. Peritoneal macrophages
(4×105 per well in quadruplicates) pretreated with human AAT (0.5 mg/ml)
were incubated with recombinant gp96 (50 pM) for 48 h. Inflammatory
mediators contained in the supernatants were measured by multiplex ELISA.
CT, untreated cells. (C) Activation markers. Peritoneal macrophages (2×106
per well in quadruplicates) pretreated with human AAT (0.5 mg/ml) were
stimulated with recombinant gp96 (50 pM) for 48 h. Cells were then stained
for surface markers. CT, untreated cells. Representative FACS dot plots,
pooled results from three independent experiments. Mean±SEM, *p< 0.05.
IL-10 (1.21± 0.03-fold from gp96-stimulated). Surface markers
are depicted in Figure 1C. As shown, gp96 elicited an increase in
surface CD40 (8.78± 0.15-fold) and MHC class II (3.05± 0.15-
fold) compared to untreated control cells. On the other hand,
hAAT-treated cultures displayed lower surface levels of MHC class
II and CD40 (1.61± 0.14-fold and 1.43± 0.03-fold, respectively,
p< 0.05 for both).
hAAT DIMINISHES gp96-DEPENDENT INFLAMMATION IN VIVO
Cecal puncture, a modification of the sepsis model cecal ligation
and puncture, evokes non-lethal systemic inflammation. Here,
experimental groups included sham-operated mice, CP in the
presence or absence of hAAT (60 mg/kg i.p., 24 h prior to CP)
and CP in the presence or absence of hAAT with an added single
dose of recombinant gp96 (80µg/kg, 24 h after CP for the pur-
pose of further aggravation of the inflammatory response in a
gp96-dependent manner). At 72 h from CP, lavage was performed
and recovered peritoneal cells were analyzed by FACS; surface lev-
els of CD40 and MHC class II on F4-80+/CD11b+ cells are shown
in Figure 2A.
As shown, CP significantly elevated surface expression of
MHC class II and CD40 in comparison to sham-operated mice.
Moreover, a significant increase in the expression of TLR2, TLR4,
and CD86 was observed (Figure A1 in Appendix). The inflam-
matory phenotype of CP-treated mice was exacerbated by the
addition of exogenous gp96 (CD40 and MHC class II rose by
1.28± 0.07-fold and by 1.34± 0.05-fold, respectively, compared
to the CP group). In contrast, treatment with hAAT reduced sur-
face expression levels of MHC class II and CD40 in CP-operated
mice, and demonstrated a similar trend in mice treated with sys-
temic gp96, as illustrated by reduction of MHC class II and CD40
to near-background levels.
Serum cytokine levels were determined at 72 h from CP
(Figure 2B) and appeared to reflect the changes observed in cell-
surface markers. For example, the addition of exogenous systemic
gp96 to CP-operated mice elevated IL-1β 3.84± 1.11-fold, IFNγ
1.84± 0.25-fold, IL-6 1.24± 0.13-fold, and IL-12p70 2.25± 0.14-
fold compared to the CP group. In contrast, hAAT-treated mice
demonstrated a significant decrease in pro-inflammatory serum
cytokine levels.
hAAT DIMINISHES gp96-DRIVEN ISLET AND BMDC INFLAMMATION
IN VITRO
In a simplified representation of an islet graft microenviron-
ment, gp96 was added to resting primary mouse pancreatic islets
(Figure 3A) and to a mixed co-culture of islets and BMDCs
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FIGURE 2 |The effect of hAAT on inflammatory responses during the
cecal puncture (CP) model. CP was performed by inflicting a uniform-size
at a constant position of the cecum in mice that were divided into the
following groups: untreated sham-operated mice (Sham, n=2), untreated
CP-operated mice (n=4), mice pretreated with hAAT (60 mg/kg), and then
CP-operated (n=5), and CP-operated mice that were also introduced with
recombinant gp96 (80µg/kg i.p., once, 24 h after the surgical procedure).
(A) Peritoneal cells. Cells were collected from the peritoneal cavity by
lavage 72 after CP and immediately stained for surface activation markers.
Representative dot plots are shown. Bottom, pooled results are
presented. (B) Serum cytokines. Cytokine concentrations in the serum
were evaluated 72 h after CP using multiplex ELISA. Representative
results out of two independent experiments. Mean±SEM, *p<0.05,
**p<0.01, ***p<0.001.
(Figure 3B) for 48 h. Cell cultures were pretreated with hAAT
or medium overnight. The inflammatory response was evalu-
ated by cytokine accumulation, and islet viability was evaluated
by accumulated insulin. As shown in Figure 3A, cultured islets
introduced to gp96 displayed increased release of inflammatory
mediators (IL-1α increased 4.34± 3.2-fold, IL-1β 5.05± 0.01-
fold, IL-6 42.4± 0.004-fold, TNFα 4.22± 0.002-fold, and IL-17
4.41± 0.9-fold, compared to resting islets). Accordingly, under
these conditions, islets displayed loss of function in the form
of reduced insulin release (2.35± 0.04-fold lower levels in com-
parison to resting islets). In contrast, in the presence of hAAT,
islets exposed to gp96 demonstrated a decrease in inflammatory
mediators (IL-1α by 1.64± 0.23-fold, IL-1β 6.16± 0.02-fold, IL-6
14.76± 0.013-fold, TNFα 2.69± 0.05-fold, and IL-17 3.61± 0.07-
fold, compared to gp96-treated islets); islets also appeared to have
partially retained insulin release, compared to gp96-treated islets.
A similar trend was observed in a mixed co-culture contain-
ing BMDCs and islets (Figure 3B). Introduction of gp96 to
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FIGURE 3 | Exogenous gp96 mediates inflammatory responses
and impairs insulin release from pancreatic islets. Primary mouse
islets (30 per well in triplicates) were incubated in the presence or
absence of BMDCs (4×105 per well) that were pretreated with
human AAT (0.5 mg/ml). Cells were incubated with recombinant gp96
(50 pM) for 48 h. Inflammatory mediators and insulin levels were
determined by multiplex ELISA and standard ELISA, respectively. CT,
untreated cells. (A) Islets, (B) co-culture; representative results from
four independent experiments. Mean±SEM, *p<0.05, **p<0.01,
***p<0.001.
co-cultures resulted in an increase in the release of inflamma-
tory mediators (IL-1α 9.95± 0.21-fold, IL-1β 12.05± 1.12-fold,
IL-12p70 63.73± 12.33-fold, TNFα 88.92± 25.71-fold, and IL-
17 6.3± 0.58-fold, compared to resting islets); this was accom-
panied by a decrease in accumulated insulin levels. On the
other hand, in the presence of hAAT, a decrease in the release
of inflammatory mediators was observed (IL-1α 1.32± 0.03-
fold, IL-1β 1.48± 0.02-fold, IL-12p70 1.87± 0.04-fold, TNFα
1.75± 0.06-fold, and IL-17 1.75± 0.15-fold, compared to co-
culture introduced to gp96). In addition, in the presence of hAAT,
an elevation in IL-10 was observed (1.48± 0.08-fold increase,
compared to gp96-treated cells). Moreover, hAAT-treated co-
cultures retained insulin release in comparison to gp96-treated
co-cultures.
MEMBRANE-BOUND gp96 IS ELEVATED DURING INFLAMMATION AND
BINDS hAAT
Membrane-bound gp96 was readily detected in both CD11b+
cells and CD11c+ cells in a cytokine-stimulation assay in vitro
(Figure 4A) and in a skin transplantation model in vivo
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FIGURE 4 | hAAT regulates membrane-bound gp96 levels under
inflammatory conditions in vitro and after allogeneic skin
transplantation in vivo; direct binding of hAAT to gp96 on cell
membranes. (A) Cell culture study. Primary BMDCs (2×106 per well) were
pretreated with human AAT (0.5 mg/ml) and stimulated with IL-1β combined
with IFNγ (5 ng/ml each) for 48 h. CT, untreated cells. Left, representative
FACS analysis dot plots and pooled results from three independent
experiments. Right, representative histograms of CD11c-positive cells.
(B) Skin allograft model. Skin from BALB/c mice (H-2d) was stitched into the
inner side of the peritoneal cavity wall of C57BL/6 mice (H-2b). Mice were
either untreated or pretreated (hAAT, 60 mg/kg). Seventy-two hours after
transplantation, lavage was performed and collected cells were examined for
levels of membrane-bound gp96 by FACS analysis. Representative dot plots
and pooled results out of two independent experiments. (C) Non-cellular
binding assay. ELISA-plate wells were coated with gp96 (0–4µg/ml) for 16 h
and then incubated for 3 h with hAAT (1 ng/ml). Captured hAAT was
determined by HRP-conjugated anti-hAAT antibody. (D) Cell membrane-bound
hAAT. Primary peritoneal macrophages (2×106 per well in quadruplicates)
were incubated with hAAT (0.5 mg/ml) for 16 h and then stained with
anti-hAAT antibody. hAAT binding to cell membranes was evaluated by FACS.
CT, untreated cells. Representative results out of three independent
experiments. (E) Pre-complexed hAAT:gp96. Freshly isolated primary mouse
islets (30 per well in triplicates) or macrophages (4×105 per well in
quadruplicates) were incubated with recombinant gp96 (50 pM) in the
presence or absence of hAAT (0.5 mg/ml) or incubated with a complex of
hAAT and gp96 (hAAT:gp96 at 0.5 mg/ml and 50 pM, respectively, for 1 h).
Cells were analyzed 48 h later. CT, untreated cells. Representative results
from three independent experiments. Mean±SEM, *p<0.05, **p<0.01.
(Figure 4B). In both setups, hAAT was assessed for its effects
on membrane-bound gp96 levels, as well as its association
with gp96.
Bone marrow derived dendritic cells were pretreated with hAAT
or medium overnight, then incubated in the presence of IL-
1β and IFNγ (5 ng/ml each) for 24 h. Cells positive for surface
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gp96 were determined by direct FACS analysis using anti-gp96
PE-conjugated antibody. As shown in Figure 4A, in the presence
of IL-1β and IFNγ stimulation, cell-surface gp96 was increased in
BMDCs 1.74± 0.1-fold, compared to non-stimulated cells. How-
ever, hAAT-treated stimulated cultures exhibited a reduction in
membrane-bound gp96 (1.47± 0.14-fold from stimulated cells).
The possibility of masking gp96 from its detection-antibody by the
presence of hAAT was excluded in separate experiments, where
hAAT was directly mixed into the FACS staining buffer (not
shown).
Membrane-bound gp96 was examined in vivo in a skin allo-
graft transplantation model performed in the peritoneal cavity for
the purpose of improved access to infiltrating cell retrieval. Peri-
toneal lavage was performed 72 h later and CD11b+/F4-80+ cells
were analyzed for relative surface gp96 levels (Figure 4B). Groups
included sham-operated mice, and mice injected with hAAT or
PBS 24 h prior to skin transplantation. As shown in Figure 4B,
grafted WT mice demonstrated a 2.39± 0.21-fold increase in sur-
face expression of gp96, compared to sham-operated mice. In
contrast, hAAT-treated mice exhibited lower surface expression
of gp96, compared to PBS-treated grafted mice (1.52± 0.06-fold).
Direct binding between gp96 and hAAT was demonstrated: in a
cell-free assay (Figure 4C), cell-surface binding assay (Figure 4D),
and in a complexed form (Figure 4E). As shown, binding of hAAT
to gp96-coated wells depicted a robust binding capacity across
several orders of concentrations (hAAT:gp96 molar ratio range:
0.1–8.0) (Figure 4C). Binding to cell membrane was evaluated
using peritoneal macrophages that were incubated in the pres-
ence or absence of hAAT. As shown in Figure 4D, hAAT displayed
direct binding to the cell surface. Finally, pancreatic islets and
macrophage cultures introduced to hAAT that was pre-incubated
with gp96 displayed a similar immune response to hAAT-treated
cultures, hence a neutralization of exogenous gp96 (Figure 4E).
INHIBITION STUDIES USING gp96i DEPICT A ROLE FOR ENDOGENOUS
gp96 IN CELL STIMULATION AND IMMEDIATE LOSS OF ISLET GRAFT
FUNCTION
Calibration assays were performed in order to identify the efficient
concentration of gp96i that interferes with gp96 activity and also
enables intact cell viability (Figure 5A). Peritoneal macrophages
were exposed to the stimulatory concentration of 50 pM gp96 and
varying concentrations of gp96i. According to release of nitrile and
minimal change in cell viability, a concentration of 6.6µM gp96i
was chosen for subsequent studies (a stoichiometric excess of 132
inhibitor molecules per single target gp96).
A B C
D E
FIGURE 5 | An inhibitor of gp96 (gp96i) modulates inflammatory
responses in macrophages and islet cultures. (A) Calibration assay.
Peritoneal macrophages (4×105 per well in quadruplicates) were incubated
in the presence of recombinant gp96 (50 pM) and gp96i (0–16µM) for 24 h.
Nitrile release into supernatants was evaluated by Griess assay. Cell death
was evaluated by LDH release into the supernatants, normalized to the
output of maximal gp96i concentration. (B) Release of inflammatory
mediators. Peritoneal macrophages (4×105 per well in quadruplicates) were
pretreated with gp96i (3.3µM) and then incubated with recombinant gp96
(50 pM) for 48 h. IL-6 levels in supernatants were evaluated by ELISA.
(C) Activation markers. Peritoneal macrophages (2×106 per well in
quadruplicates) were pretreated with gp96i (3.3µM) and then incubated with
recombinant gp96 (50 pM) for 48 h. Cells were stained for surface markers.
CT, untreated cells. Representative FACS dot plots, pooled results from three
independent experiments. (D) Pancreatic islets. Freshly isolated primary
mouse islets (30 per well in triplicates) were pretreated with gp96i (3.3µM)
and then incubated with recombinant gp96 (50 pM) for 48 h. Insulin release
to supernatant was measured by ELISA. CT, untreated islets. (E) Co-culture
study. Islets (30 per well in triplicates) and peritoneal macrophages (4×105
per well) were pretreated with gp96i (3.3µM) and then incubated with
recombinant gp96 (50 pM). Forty-eight-hour later inflammatory mediators
and insulin were measured in the supernatants. CT, untreated cells.
Representative results from four independent experiments. Mean±SEM,
*p<0.05, **p<0.01.
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In order to examine whether the inhibitor can interfere
with gp96-mediated inflammatory responses in macrophages
(Figures 5B,C), cells were treated with gp96i and gp96. As shown,
gp96 caused an increase in release levels of IL-6 (22.6-fold) that
were reduced by 79% in the presence of gp96i. Pro-inflammatory
cytokines responded in a similar manner (not shown). Inducible
surface levels of CD40 were similarly affected by gp96 and the
introduction of gp96i (Figure 5C), in that the elevation caused by
gp96 was blocked by the presence of gp96i.
Response to gp96i was also examined in primary islet cul-
tures (Figure 5D) and in a co-culture of islets and macrophages
(Figure 5E). As shown, exogenous gp96 induced the release of
IL-6 from islets (9.57-fold from control), which were restored
to 3.93± 0.04-fold from resting levels by added gp96i. A reduc-
tion in accumulated supernatant insulin exhibited in the presence
of gp96 (from 2.646 to 1.628µg/ml, mean), yet insulin levels
were near-normal levels in the presence of gp96i (2.32µg/ml).
In a mixed culture, gp96 increased IL-6 release 3.91± 0.19-fold,
but only 1.38± 0.08-fold in the presence of gp96i. Accumulated
insulin was reduced in mixed cultures from 1.775µg/ml in islets
alone to 1.013µg/m in islets that were cultured together with
macrophages; gp96 further reduced the amount of insulin 1.42-
fold in the absence of gp96i, but saw intact insulin release in the
presence of gp96i.
The function of endogenous gp96 was next challenged in vivo
in a pancreatic islet transplantation model (Figure 6). In this
model, islet function can be readily observed by following the nor-
malization of circulating glucose. Islets from CBA/2J H-2k mice
were grafted under the renal capsule of hyperglycemic C57BL/6 H-
2b mice in the presence or absence of systemic gp96i (i.p., daily
from day-1, 100µg/mouse). As shown in Figure 6A, mice treated
with gp96i exhibited superior control over glucose. To examine
the function of islet grafts for 14 days, an intraperitoneal osmotic
pump that released either PBS or 100µg of gp96i every day until
depleted of the inhibitor on day 14 was instilled in the peritoneal
cavity. As shown in Figure 6B, gp96i-treated mice displayed supe-
rior prolongation of islet graft failure threshold after 14 days, com-
pared to the 8-day threshold crossing in the vehicle-treated group.
In a representative sample from each treatment group, grafts were
explanted 2 days after graft failure and analyzed for relative insulin
content by immunohistochemistry. As shown in Figure 6C, gp96i-
treated mice displayed relatively larger portions of insulin-positive
cells compared to vehicle-treated mice, although this parameter is
not quantitative.
With focus on the immune response 7 days after islets engraft-
ment, we examined splenocytes that were collected at that time
point from each treatment group. Splenic CD11b+ cells were ana-
lyzed for CD40 and MHC class II surface levels (Figure 6D),
as well as for inflammatory release products (Figure 6E). As
shown, splenocytes collected from gp96i-treated mice exhibited
a decrease in surface levels of CD40 (without reaching statistical
significance) and MHC class II (p< 0.05) compared to spleno-
cytes from vehicle-treated mice. A similar trend was observed
in release of inflammatory mediators: splenocytes collected from
gp96i-treated mice demonstrated a reduction in inflamma-
tory mediators release (IL-1β 1.75± 0.06-fold, IL-6 2.06± 0.07-
fold, IL-17 7.58± 0.01-fold, TNFα 3.26± 0.03-fold, IL-12p70
2.09± 0.04-fold, MCP-1 15.18± 0.03-fold, MIP-1α 3.57± 0.03-
fold, and RANTES 12.59± 0.03-fold compared to splenocytes
collected from vehicle-treated mice).
DISCUSSION
The beneficial effect of hAAT has been extensively reported in the
context of pancreatic islet allograft transplantation and autoim-
mune islet damage (18–20, 22, 24, 29, 30). However, the mech-
anism of hAAT activity is not yet clear. The notion that hAAT
may address circulating damage molecules emerged from the
perplexingly high concentrations of normally circulating hAAT,
particularly during the acute-phase response. We hypothesized
that, as dying cells are being continually replaced by new cells,
the set-point of hAAT levels may be providing protection from
aberrant circulating damage molecules. Immune responses that
are facilitated and enhanced by cell injury include trauma, necro-
sis or infection, and are primarily mediated by cell-originating
DAMPs (31).
The DAMP molecule, gp96, serves as one of the most abun-
dant chaperons in the normal cell. Several studies had proposed
that the release of gp96 due to tissue damage markedly increases
inflammatory responses. An example for this phenomenon can be
found in RA (9, 10). Indeed, macrophages that were introduced to
synovial fluid from RA patients, containing high levels of endoge-
nous gp96, responded with an inflammatory flare. Inhibition of
gp96 by specific antibodies in a murine model for RA resulted
in improved tissue protection. Similarly, with no apparent known
mechanism, hAAT therapy improves disease scores in a mouse
model (13, 29). The overlap in animal study outcomes between
gp96 inhibition and added hAAT suggest a possible relationship
between these two molecules.
In the current study, we present data that suggest that dur-
ing inflammatory conditions, pancreatic islets are a target of
gp96-mediated inflammatory damage, and that this aspect of
cell injury may be regulated by circulating hAAT. We show that
gp96-treated macrophage cultures display a reduced inflamma-
tory response and an elevated release of IL-10 in the presence
of added hAAT. Macrophages isolated from hAAT-treated mice
that were introduced to recombinant gp96 exhibited lower surface
expression of CD40 and MHC class II, and the animals pre-
sented with reduced inflammatory serum cytokines. The effect
of hAAT on gp96-mediated inflammatory responses was also evi-
dent in cultured pancreatic islets, affording gp96-exposed islets
with regained insulin release. A consistent trend was observed in
islets co-cultured with gp96-stimulated innate cells. Thus, islets
that are presented with highly inflammatory molecular and cellu-
lar environments are injured by extracellular gp96 and protected
by hAAT.
We next addressed endogenously expressed gp96. A dimin-
ishing effect of hAAT on cell-surface expression of gp96 under
inflammatory conditions was observed in vitro. Also, in an allo-
geneic skin transplantation model, hAAT had decreased cell-
surface expression of gp96 on macrophages that were recovered
from the transplantation site. In addition, the effect of direct
inhibition of endogenous gp96 by gp96i resulted in reduced
inflammatory responses in macrophages, islets, and co-culture
of macrophage and islets, and was demonstrated here in an islet
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A
B C
D E
FIGURE 6 | Involvement of endogenous gp96 in islet failure during islet
transplantation. Mice were rendered hyperglycemic by single-dose STZ
(225 mg/kg) and then grafted with allogeneic islets (500 islets per graft).
Vehicle, untreated recipients; gp96i, gp96i-treated recipients, n=8 per group.
(A) Immediate graft function. Average of non-fasting blood glucose levels, 2
and 7 days after islet engraftment. (B) Prolonged graft function under
continuous slow-release gp96i. Osmotic pumps were implanted in the
peritoneal cavity and released gp96i in a continuous manner for 14 days.
Representative glucose follow-up is shown, superimposed along the same
timeline over pooled results. Shaded, the 14-day time-frame of gp96i release.
(C) Day-7 of explanted graft immunohistochemistry. Red, insulin; Blue, DAPI
nuclear counterstaining. Representative images. (D) Activation markers.
Spleen-derived macrophages (1×106 per sample) were stained for activation
markers upon graft explanation on day 7. (E) Release of inflammatory
mediators. Day-7 spleen-derived macrophages were cultured for 24 h and
supernatants were allowed to accumulate cell release products. Inflammatory
mediators in the supernatants were measured by multiplex ELISA.
Mean±SEM, **p< 0.01 and ***p<0.001.
transplantation animal model. Lastly, we show that hAAT directly
binds to gp96.
Our data is supported by studies which indicate that innate
immune cells respond to gp96 with inflammation (32). Inflam-
matory mediators released from macrophages, such as IL-1β
and TNFα, play a key role in early stages of type 1 diabetes
(33). In this context, the finding of elevated surface expres-
sion of CD40 and MHC class II in the presence of gp96
could contribute to macrophage interaction with and activa-
tion by T cells and enhance antigen presentation, which in
turn might promote islet cell loss. In the present study, hAAT
appeared to have regulated gp96-induced inflammatory responses
in macrophages.
When comparing the inflammatory response mediated by
gp96-stimulated macrophages in vitro and in vivo, a consistent
profile emerges. Here, we utilized the commonly employed CP
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and ligation sepsis model, with the exception of the ligation
step, so as to induce a non-lethal milder systemic inflammatory
response. This allowed us to examine the effect of added exoge-
nous gp96 without the concern of premature cessation of the
cohort due to lethality. Indeed, a clear trend toward less-activated
immune cells had surfaced in hAAT-treated CP-operated ani-
mals. This model was one of the first to demonstrate a clear role
for DAMPs.
Although β-cell destruction in type 1 diabetes is mainly medi-
ated by specific cytotoxic T cells and is associated with production
of autoantibodies by B lymphocytes, the innate inflammatory
response also serves a key role in pancreatic islet injury,and appears
to be aggravated further by the presence of DAMP molecules.
However, not enough data has been collected thus far regarding
the sensitivity of resident immune cell populations within islets
to damage signals released from injured β-cells. We addressed
these aspects in the present study using mixed islets and innate
cell co-cultures and observed a consistent protective effect in the
presence of added hAAT. Our data thus support the notion that
hAAT may be a regulator of inflammatory conditions in pancre-
atic islets during various injurious conditions, with a predominant
capacity to blunt innate cell activation by endogenous mediators
of damage.
We also addressed the appearance of gp96 on cell membranes.
Cell-surface expression of gp96 under inflammatory condition
was shown to correlate with tissue damage. CD14+ cells collected
from damaged tissue demonstrated gp96 on their cell mem-
branes, unlike cells from a non-inflamed tissue (10, 13). In a
transgenic model that involves expression of cell-surface gp96 in
APCs, the development of an autoimmune disease resembling SLE
was shown to spontaneously evolve. In addition, in this model,
resting dendritic cells expressed high levels of surface gp96 and
released excess inflammatory mediators in vitro (12). Here, we
show that hAAT reduces cell-surface expression of gp96 in BMDCs
under inflammatory conditions and in peritoneal macrophages
isolated from allogeneic transplantation sites. This phenomenon
could be attributed to the regulatory effect of hAAT on BMDCs
in vitro, as well as in the context of an allogeneic skin trans-
plantation model, or it could reflect direct binding between gp96
and hAAT.
Direct interaction between gp96 and hAAT has been demon-
strated in plasma samples collected from patients with type 1
diabetes (14, 34), as well as in the normal secretory pathway of
intracellular hAAT (35). A similar result was illustrated in our
experimental setting; gp96 pre-incubated with hAAT alone dis-
played loss of function; it behaved in a similar manner as gp96
that was added to cultures pretreated with hAAT. A direct inter-
action between gp96 and hAAT could also occur on the cell
membranes, since both proteins have been shown to localize
to cell-surface lipid rafts (36, 37). Although hAAT is primar-
ily known to interact with its target proteases through a short
protease-specific sequence of amino-acids, hAAT was recently
shown to bind IL-8, ADAM17, and FcγRIIIb by virtue of unique
bindings sites unrelated to protease inhibition (38); yet, none
of the reported binding sites appears to satisfy binding con-
ditions of hAAT to gp96 in silico. Further work must be per-
formed in order to identify the domain in hAAT that interacts
with gp96.
Extracellular inhibition of gp96 was examined by a polypep-
tide, gp96i, designed to directly interact with gp96 (26). Here,
we demonstrate that gp96i reduces extracellular gp96-mediated
inflammatory responses in peritoneal macrophages. The benefi-
cial effect of gp96i was also demonstrated in a sterile pancreatic
islet transplantation model. We show here for the first time that
inhibition of endogenous gp96 by a specific inhibitor improves
immediate islet graft function. Improved islet function could be
attributed to low concentrations of IL-1β, a cytokine that is known
to mediate islet injury. Recently, it has been reported that neutral-
izing antibodies to the DAMP molecule, high-mobility group box
1 exhibited similar outcomes to gp96 blockade (39). These data
suggest that cell injury may be sensed by pancreatic islets and then
become responsible for amplifying local immune cell responses,
a phenomenon that may be intended to clear massive cell loss
during islet transplantation. The importance of inflammation-
mediating receptors, such as TLR2/4, on pancreatic islet cells
post-transplantation has been demonstrated in several studies
(39–41). Here, continuous treatment with gp96i by an intraperi-
toneal osmotic pump resulted in superior graft function, at least
as long as gp96i was released from the apparatus. The precise con-
nection between gp96 and islet damage during transplantation
deserves further investigation.
Considering that hAAT provides marked benefit in multiple
diabetes models, our findings provide immunological relevance
to the interaction between hAAT and human gp96 reported by
Finotti et al. to occur in diabetic individuals. Indeed, our data sug-
gest that hAAT may serve as natural regulator of gp96-mediated
inflammatory responses. Additionally, we suggest that gp96 may
play a role in the immune response during allogeneic transplan-
tation and that gp96 can impair immediate graft function. Taken
together, this important activity of hAAT may place the clinically
available molecule for consideration as an added therapeutic in
pathologies that are intensified by tissue damage, such as ischemic
heart disease (16), graft-versus-host disease (17), and other novel
clinical indications (15).
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APPENDIX
FIGURE A1 |The effect of hAAT onTLR2 andTLR4 during cecal puncture
(CP) model. CP was performed with the following groups: untreated
sham-operated mice (Sham, n=2), untreated CP-operated mice (n=4), mice
pretreated with hAAT (60 mg/kg), and then CP-operated (n=5). Also,
CP-treated mice were introduced recombinant gp96 (i.p., 80µg/kg, once, 24 h
after the surgical procedure). Peritoneal cells were obtained 72 after CP by
lavage and immediately stained for surface activation markers.
Representative dot plots are shown. Bottom, pooled results. Representative
results out of two independent experiments. Mean±SEM, *p<0.05,
**p<0.01, ***p< 0.001.
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